HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kolbert, K. S. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Kolbert, K. S. Articles by Larson, S. M.

Prediction of Absorbed Dose to Normal Organs in Thyroid Cancer Patients Treated with ¹³¹I by Use of ¹²⁴I PET and 3-Dimensional Internal Dosimetry Software

¹ Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York; and ² Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: Katherine S. Kolbert, MS, Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail: katherinenyc{at}att.net

The objective of this work was to determine normal organ ¹³¹I dosimetry in patients undergoing radioiodide therapy for thyroid cancer by use of serial scanning with ¹²⁴I PET. Methods: A total of 26 patients who had papillary and follicular metastatic thyroid cancer and who were already enrolled in a Memorial Sloan-Kettering Cancer Center ¹³¹I thyroid cancer protocol were selected for this study. Imaging before ¹³¹I therapy consisted of multiple, whole-body ¹²⁴I PET studies over a period of 2–8 d, an ¹⁸F-FDG PET scan and, for some, a diagnostic CT scan. With a set of in-house–developed software tools (3-dimensional internal dosimetry [3D-ID] and Multiple Image Analysis Utility [MIAU]), the following procedures were performed: all PET emission and transmission and CT image sets were aligned; half-life–corrected tomographic images of ¹³¹I activity were integrated voxel by voxel to produce cumulated ¹³¹I activity images; and the latter images were, in turn, convolved with a ¹³¹I electron–photon point kernel to produce images of ¹³¹I dose distribution. Cumulated activity values and calculated residence times obtained from our patient-specific dosimetry software (3D-ID) were used as inputs to OLINDA, and volume difference–adjusted comparisons were made between the mean dose estimates. Results: With 3D-ID, dose volume histograms and mean doses were calculated for 14 organs, and results were expressed in Gy/GBq. The highest mean dose, 0.26 Gy/GBq, was seen in the right submandibular gland, whereas the lowest mean dose, 0.029 Gy/GBq, was seen in the brain. Conclusion: This is the first comprehensive study of normal organ dosimetry in patients by use of a quantitative tomographic imaging modality.

Key Words: ¹³¹I normal organ dose • thyroid cancer • ¹²⁴I PET • radioimmunotherapy

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

Spatial Dose Mapping for Individualizing Radioiodine Treatment

Michael Lassmann and Heribert Hänscheid
JNM 2007 48: 2-4. [Full Text]  

This article has been cited by other articles:

				M. A. Walter, C. P. Turtschi, C. Schindler, P. Minnig, J. Muller-Brand, and B. Muller The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study J. Nucl. Med., October 1, 2007; 48(10): 1620 - 1625. [Abstract] [Full Text] [PDF]